2019
DOI: 10.1038/s41429-019-0227-3
|View full text |Cite
|
Sign up to set email alerts
|

Mechanism of action of nucleoside antibacterial natural product antibiotics

Abstract: Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
19
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 29 publications
(19 citation statements)
references
References 91 publications
(92 reference statements)
0
19
0
Order By: Relevance
“…43,372−375 It also inhibits MraY. 155,158,163,376 Nonetheless, tunicamycin is not suitable as an antibiotic due to eukaryotic toxicity. Its structural modification favorably altered this balance to give tunicamycin analogs showing βlactam synergy, 377 confirming previous observations showing a 16−64-fold MIC decrease for β-lactams for MRSA bacteria in the presence of 0.4 mg L −1 tunicamycin.…”
Section: S Aureus Cell Envelope Beyond the Peptidoglycanmentioning
confidence: 99%
See 2 more Smart Citations
“…43,372−375 It also inhibits MraY. 155,158,163,376 Nonetheless, tunicamycin is not suitable as an antibiotic due to eukaryotic toxicity. Its structural modification favorably altered this balance to give tunicamycin analogs showing βlactam synergy, 377 confirming previous observations showing a 16−64-fold MIC decrease for β-lactams for MRSA bacteria in the presence of 0.4 mg L −1 tunicamycin.…”
Section: S Aureus Cell Envelope Beyond the Peptidoglycanmentioning
confidence: 99%
“…Each of these four enzymesUppS, UppP, MraY, and MurG , have been explored intensively with respect to inhibition by both synthetic and natural product (antibiotic) molecules. The renewed interest in structure–activity development of the nucleoside-mimetic natural product inhibitors of MraY , and the recognition that numerous antibiotics interfere with peptidoglycan biosynthesis by complexation with the undecaprenol diphosphate (in both Gram-positive , and Gram-negative bacteria , ) and/or Lipid II ,,, ) are notable recent developments. Indeed, the recognition of the fastidiousness of the intertwined biosynthetic cycles for Lipid II synthesis, , for Lipid II assembly into the peptidoglycan, and for peptidoglycan recycling (with preeminent natural product antibacterials targeting within each cycle) have led to substantial effort toward answering whether concurrent inhibition of two of these cycles (and their regulatory systems) achieves meaningful antibiotic synergism.…”
Section: Gram-positive Cell Envelopementioning
confidence: 99%
See 1 more Smart Citation
“…The latter is inserted into the PG layer as a building unit by various penicillin-binding proteins (PBPs) ( Sauvage et al, 2008 ). MraY is a well-studied target for antibiotics and the bacteriophage ϕX174 for host cell lysis in E. coli ( Bernhardt et al, 2000 ; Bugg and Kerr, 2019 ). Because of its rigid nature, PG synthesis and degradation occur constantly during cell growth and division for the morphogenesis of the newly formed cell poles during cell constriction.…”
Section: Introductionmentioning
confidence: 99%
“…Pacidamycins 1 and 5, cationic peptides with homology to the bacteriophage øX174 lysis protein Arg-Trp-x-x-Trp motif, believed to bind the cytoplasmic surface of MraY and thereby inhibiting it (Figure 1 3 ) (Rodolis et al, 2014; Bugg and Kerr, 2019), had little effect on either growth rate or chloroplast division (data not shown). Likewise, Murgocil, a 448Da steroid-like molecule, which inhibits peptidoglycan synthesis in Staphylococcus aureus and is predicted to bind in the MurG active site blocking UDP-GlcNAc access (Figure 1 5 ), when tested at 1, 5 and 25 µg.ml-1 was found to have little effect on protonemata phenotype (Figure 2, F).…”
mentioning
confidence: 97%